An in-vivo pilot study into the effects of FDG-mNP in cancer in mice

WOS: 000442202100030
PubMed ID: 30125303
Purpose Previously, fluorodeoxy glucose conjugated magnetite nanoparticles (FDG-mNPs) injected into cancer cells in conjunction with the application of magnetic hyperthermia have shown promise in new FDG-mNPs applications. The aim of this study was to determine potential toxic or unwanted effects involving both tumour cells and normal tissue in other organs when FDG-mNPs are administered intravenously or intratumourally in mice. Materials and methods FDG-mNPs were synthesized. A group of six prostate-tumour bearing mice were injected with 23.42 mg/ml FDG-mNPs (intravenous injection, n = 3; intratumoural injection into the prostate tumour, n = 3). Mice were euthanized and histological sampling of tissue was conducted for the prostate tumour, as well as for lungs, lymph nodes, liver, kidneys, spleen, and brain, at 1 hour (n = 2) and 7 days (n = 4) post-injection. A second group of two normal (non-cancerous) mice received the same injection intravenously into the tail vein and were euthanised at 3 and 6 months post-injection, respectively, to investigate if FDG-mNPs remained in organs at those time points. Results In prostate-tumour bearing mice, FDG-mNPs concentrated in the prostate tumour, while relatively small amounts were found in the organs of other tissues, particularly the spleen and the liver; FDG-mNP concentrations decreased over time in all tissues. In normal mice, no detrimental effects were found in either mouse at 3 or 6 months. Conclusion Intravenous or intratumoural FDG-mNPs can be safely administered for effective cancer cell destruction. Further research on the clinical utility of FDG-mNPs will be conducted by applying hyperthermia in conjunction with FDG-mNPs in mice.
Memorial Sloan Kettering Cancer Centre, Department of Radiology; NIH/NCI Cancer Center Support Grant [P30 CA008748]; NIH Small-Animal Imaging Research Program (SAIRP)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24 CA83084]; NIH Prostate SPORE [P50-CA92629]; Ege University, Institute of Nuclear Sciences, Department of Nuclear Applications, Turkey; School of Engineering and Applied Science, Aston University, Birmingham, UK; Division of Vascular & Endovascular Surgery Department of Cardiac, Thoracic & Vascular Surgery National University Heart Centre, Singapore
This research was funded by Memorial Sloan Kettering Cancer Centre, Department of Radiology, and the NIH/NCI Cancer Center Support Grant P30 CA008748, NIH Small-Animal Imaging Research Program (SAIRP), R24 CA83084; NIH Prostate SPORE, P50-CA92629; Ege University, Institute of Nuclear Sciences, Department of Nuclear Applications, 35100 Turkey; School of Engineering and Applied Science, Aston University, Birmingham, UK, B4 7E and Mr Julian Wong FRCS, Division of Vascular & Endovascular Surgery Department of Cardiac, Thoracic & Vascular Surgery National University Heart Centre, Singapore 1E Kent Ridge Road NUHS Tower Block, Level 9, Singapore 119228.; This research was funded by Memorial Sloan Kettering Cancer Centre, Department of Radiology, and the NIH/NCI Cancer Center Support Grant P30 CA008748, NIH Small-Animal Imaging Research Program (SAIRP), R24 CA83084; NIH Prostate SPORE, P50-CA92629; Ege University, Institute of Nuclear Sciences, Department of Nuclear Applications, 35100 Turkey; School of Engineering and Applied Science, Aston University, Birmingham, UK, B4 7E and Mr Julian Wong FRCS, Division of Vascular & Endovascular Surgery Department of Cardiac, Thoracic & Vascular Surgery National University Heart Centre, Singapore 1E Kent Ridge Road NUHS Tower Block, Level 9, Singapore 119228. The authors would like to thank the staff at Aston University's Biomedical research unit for animal provision and maintenance. The authors also would like to acknowledge Charlotte Bland and the Aston Research Centre for Healthy Ageing (ARCHA) imaging facility for their assistance with our tissue analysis studies.